Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines

COLLEGEVILLE, Pa., & HOERSHOLM, Denmark, Jan. 12 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE ), and Santaris Pharma today announced that the companies have entered into a worldwide strategic alliance to discover, develop and commercialize new medicines bas...

Santaris in Medical Technology

Another LNA-based RNA Inhibitor Enters Clinical Trials

... COPENHAGEN, March 20 /PRNewswire/ -- santaris Pharma announced today that the fourth LNA-based d... Survivin inhibitor, which is jointly developed by santaris Pharma and Enzon Pharmaceuticals. The U.S. Food an...lls" http://www.santaris.com About santaris Pharma ...

Santaris Pharma presents positive preclinical data on SPC2996 at the American Association for Cancer Research

...ymphocytic Leukaemia COPENHAGEN, 18 April 2007 - santaris Pharma, the Danish biopharmaceutical company devel...ts at the University of Duisberg-Essen in Germany, santaris researchers reported that white blood cells obtain...tact: Dr. Keith McCullagh President & CEO, santaris Pharma, Tel: +45 4517 9819, Cell:+44 7939 573548...

Santaris Pharma Presents Positive Clinical Data on SPC2996 in Chronic Lymphocytic Leukaemia

...y of Adult Leukaemia Copenhagen, 6th June 2007 - santaris Pharma, the Danish biopharmaceutical company, anno...nd more common tumour type. Dr Lene Worsaae Dalby, santaris Pharma's Vice-President of Clinical Development, s...ntrations. Following this second Phase I/II study, santaris expects to commence randomised Phase II studies in...

Santaris in Biological Technology

Santaris Pharma - Interim Report for the Period 1 January to 30 June 2009

... is scheduled to commence in Q3 2009. - santaris Pharma's new lead candidate SPC4955 targeting ...20/344344 ) During the first half of 2009 santaris Pharma continued to make satisfactory progress in ...tis virus replication in the liver. In April 2009, santaris Pharma completed a Phase I First-in-Man single dos...

LNA-Based HIF-1 Alpha Inhibitor Shows Early Signs of Clinical Benefit

... COPENHAGEN, June 4 /PRNewswire/ -- santaris Pharma today announced that the cancer drug EZN-29...ha, jointly developed by Enzon Pharmaceuticals and santaris Pharma A/S - was well tolerated and showed early s...edules. The HIF-1 alpha inhibitor is licensed from santaris Pharma A/S. The collaboration between...

Santaris Pharma Director Appointed Adjunct Professor in RNA Biology at the University of Aalborg, Denmark

... COPENHAGEN, June 3 /PRNewswire/ -- santaris Pharma and Copenhagen Institute of Technology, Aal...enmark, announced today that Director of microRNA, santaris Pharma, Sakari Kauppinen, has been appointed Adjun...Sakari Kauppinen, Director of MicroRNA Research at santaris Pharma said: "I feel very honored to be app...

Santaris Pharma Delivers Six LNA-Based RNA Inhibitors to Enzon Pharmaceuticals Ahead of Schedule

...drugs within a short time span," said Henrik 0rum, santaris Pharma's Chief Scientific Officer. santaris Pharma and Enzon Pharmaceuticals signed their agreement in 2006. As part of the agreement santaris Pharma retains the lucrative commercial rights to ...

LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs

... COPENHAGEN, April 20 /PRNewswire/ -- santaris Pharma announced today promising findings on the i...ated RNAs, including microRNAs," said Henrik 0rum, santaris Pharma's Chief Scientific Officer. "These results ...rapeutics within a range of disease areas." santaris Pharma is a leader within microRNA research and is...

Affitech Appoints Dr. Keith McCullagh as Chairman

...preneurial track record in the biopharmaceutical industry, most recently at santaris Pharma in Denmark, where as CE0 he has played a major role in establishing ...ence industry. Most recently, from October 2003 to June 2008, he was CEO of santaris Pharma, a Danish biopharmaceutical company. From 2000 to 2003 he was execut...

IBF Conferences Inc*International Business Forum and BioEnterprise Corporation present the 2nd Annual Global Healthcare Investing Conference

...y Sector Shanghai, China GammaStar Medical Devices Group Ltd. Hoersholm, Denmark santaris BioPharmaceutical Pharmaceutical California, USA Napo Pharmaceutical BioPharmaceutical ...

Santaris Pharma to Present at 10th Annual Biotechnology Industry Organisation CEO & Investor Conference - February 11th, 2008

... COPENHAGEN, Denmark, Feb. 11 /PRNewswire/ -- santaris Pharma, the Danish biopharmaceutical company devel... February 11th-13th, 2008. A live webcast of the santaris Pharma presentation may be accessed from the news ...ived and available after the presentation. About santaris Pharma ...

Danish Hotspot in Personalized Medicine

...ine in Denmark: Within diagnostics: Dako, Exiqon, FluimediX and Medical Prognostic Institute. Within drug discovery: Genmab, Novo Nordisk, Pharmexa, santaris Pharma and TopoTarget. For further information: Vibeke Dalhoff Tel.:+45-33-26-87-22 +45-61-26-464 email: vda@copcap.com Gitte Pedersen tel...